Shenzhen BioX Medical Co., Ltd. stands as a paradigm of innovation in the global Surgical Pathology Systems market. As a professional manufacturer specializing in molecular diagnostic analysis systems and genetic testing solutions, BioX Medical has bridged the gap between traditional histopathology and the future of precision medicine. Established in 2017 and headquartered in Shenzhen—the "Silicon Valley of China"—the company leverages a world-class ecosystem for biotechnology and advanced manufacturing to deliver high-performance diagnostic tools.
Occupying a 9,000 square meter state-of-the-art facility with over 200 specialized employees, our organization is dedicated to the R&D of molecular diagnostic technologies. Our expertise serves a diverse global clientele including clinical laboratories, Tier-1 hospitals, research institutions, and biotechnology conglomerates. In the context of E-E-A-T (Experience, Expertise, Authoritativeness, and Trustworthiness), BioX Medical represents a trusted partner for health systems seeking scalable, accurate, and compliant diagnostic infrastructure.
Multidisciplinary teams integrating AI, molecular biology, and mechanical engineering to create the next generation of automated diagnostic platforms.
Exporting to Europe, North America, and Asia-Pacific, adhering to stringent international standards for medical device safety and efficacy.
Utilizing Industry 4.0 principles to ensure rapid lead times and high consistency across molecular diagnostic and pathological product lines.
Integration of high-resolution imaging and cloud-based data management for pathology slides, allowing for remote diagnostics and expert collaboration.
Converging surgical pathology with genomic data. Our PCR systems (like the Leia-X4) enable real-time analysis of biomarkers directly alongside tissue samples.
Implementing deep-learning algorithms to assist pathologists in identifying cellular patterns, reducing human error, and accelerating turnaround times (TAT).
The roadmap for Surgical Pathology Systems is moving toward "Total Laboratory Automation." BioX Medical is at the forefront of this transition, focusing on modular designs that allow facilities to scale from manual processes to fully automated workflows. Our future development focuses on Information Gain—providing clinicians with more data per sample than ever before through multiplexed detection kits and high-sensitivity optical analysis.
Founded
Sqm Factory
Experts
Countries Served
In the highly regulated world of medical diagnostics, compliance is not optional. BioX Medical ensures that all pathology systems meet the rigorous demands of the global market, including CE-IVD, ISO 13485, and localized health authority requirements in the Middle East, Latin America, and Africa. Our solutions extend beyond the machine; we provide a holistic ecosystem including:
The resilience of the Surgical Pathology Systems supply chain is a critical concern for global healthcare providers. By centralizing our manufacturing in Shenzhen, BioX Medical benefits from a condensed supply chain where specialized components—from high-precision optical sensors to automated fluidic modules—are sourced and integrated within a 50km radius. This "Factory 4.0" approach enables us to mitigate global logistics risks and maintain consistent quality through Comprehensive Quality Control procedures at every stage of design and inspection.
Our facility's automation levels ensure that even complex systems like the Acid Purification Systems or qPCR platforms are manufactured with microscopic precision, reducing the failure rate and extending the lifecycle of the equipment in heavy-use clinical environments.
BioX Medical
